Analytical Data
-
Gene name
CYP4Z1
- Application
-
Alternative Names
CYP4Z1; UNQ3060/PRO9882Cytochrome P450 4Z1; EC 1.14.14.1; CYPIVZ1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86W10
-
Expression Region
1-505aa
-
AA Sequence
MEPSWLQELMAHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAHWFYGHKEFYPVKEFEVYHKLMEKYPCAVPLWVGPFTMFFSVHDPDYAKILLKRQDPKSAVSHKILESWVGRGLVTLDGSKWKKHRQIVKPGFNISILKIFITMMSESVRMMLNKWEEHIAQNSRLELFQHVSLMTLDSIMKCAFSHQGSIQLDSTLDSYLKAVFNLSKISNQRMNNFLHHNDLVFKFSSQGQIFSKFNQELHQFTEKVIQDRKESLKDKLKQDTTQKRRWDFLDILLSAKSENTKDFSEADLQAEVKTFMFAGHDTTSSAISWILYCLAKYPEHQQRCRDEIRELLGDGSSITWEHLSQMPYTTMCIKECLRLYAPVVNISRLLDKPITFPDGRSLPAGITVFINIWALHHNPYFWEDPQVFNPLRFSRENSEKIHPYAFIPFSAGLRNCIGQHFAIIECKVAVALTLLRFKLAPDHSRPPQPVRQVVLKSKNGIHVFAKKVC
-
Molecular Weight
85.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP4Z1, a member of the cytochrome P450 family, has garnered attention due to its unique role in drug metabolism and potential association with various diseases. This enzyme is primarily expressed in the human liver and plays a crucial part in the oxidative metabolism of a diverse range of xenobiotics, as well as endogenous compounds. Recent research has highlighted its involvement in the metabolic activation of certain prodrugs and the metabolism of specific fatty acids, linking CYP4Z1 to pathways of inflammation and cancer. The recombinant expression of CYP4Z1 is pivotal for understanding its catalytic mechanisms, substrate specificity, and role in pharmacogenomics. By producing this enzyme in a recombinant system, researchers can perform detailed studies to delineate the structure-function relationship and identify potential inhibitors or activators, thus paving the way for therapeutic applications. Additionally, investigating the polymorphisms associated with CYP4Z1 may offer insights into interindividual variability in drug responses and toxicity. Understanding the functional characteristics of CYP4Z1 through recombinant protein studies could ultimately contribute to the development of personalized medicine strategies and enhance our knowledge of its implications in human health.
